Compare ING Groep NV (ING) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs BIO-TECHNE Corp — how do they compare? ING Groep NV trades at $33.15 (market cap $93.76B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: ING Groep NV is far larger — about 8.3× BIO-TECHNE Corp's market cap, and ING Groep NV pays the higher dividend (3.95%). Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 93 Days and BIO-TECHNE Corp for 63 Days on average.
| ING | TECH | |
|---|---|---|
Market Cap | $93.76B | $11.36B |
Volume | 4,620,220 | 5,390,331 |
Sector | Financials | Health |
52-Week High | $37.27 | $72.61 |
52-Week Low | $23.66 | $43.31 |
Typical Hold Time | 93 Days | 63 Days |
Enterprise Value | $236.48B | $11.39B |
Dividend Yield | 3.95% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.92, down 2.81% on the day, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $22.90 billion in 2025, with net income of $6.33 billion and a net margin of 28.34%. Recent earnings beats and a raised 2027 ROE target above 16% highlight operational strength, though cash flow trends show persistent net outflows.
The outlook is mixed: strong profitability and analyst consensus (64.71% buy ratings) support upside, but bearish technicals and regulatory scrutiny in Australia pose risks. Valuation appears reasonable with a P/E of 13.09, offering a potential entry for long-term investors focused on execution of growth initiatives.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
